Immunometabolic Remodeling in Osteosarcopenia: Inflammaging, Mitochondrial Dysfunction, Gut-Derived Metabolites and Therapeutic Opportunities
Metabolites · 06.08.2026 · 16 (8) · 556
DOI: 10.3390/metabo16080556 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Metabolites, online erschienen am 06.08.2026. Verfasst von Yichi Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Heilongjiang University of Chinese Medicine, Harbin 150040, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heilongjiang Provincial Key Research and Development Pro-gram (Innovation Base), Heilongjiang Provincial Key Research and Development Program.
Abstract (Originalsprache)
Osteosarcopenia—defined as the coexistence of sarcopenia and osteoporosis—is increasingly recognized as a clinically important geriatric syndrome associated with falls, fractures, frailty, disability, and mortality. Beyond the simple coexistence of bone and muscle loss, emerging data suggest that osteosarcopenia may reflect systemic dysregulation of the bone–muscle–immune–metabolic network. In this narrative review, we synthesize evidence linking inflammaging, immune-cell polarization, mitochondrial dysfunction, nutrient metabolic dyshomeostasis, and gut-derived metabolites to the pathogenesis of osteosarcopenia. Multiple pathological processes—including chronic low-grade inflammation, Th17/Treg imbalance, macrophage polarization, oxidative stress, impaired mitophagy, insulin resistance, ectopic fat accumulation, and altered microbial metabolites—may converge to disrupt bone–muscle crosstalk. Notably, direct evidence from osteosarcopenic populations remains limited, and many mechanistic insights are extrapolated from osteoporosis, sarcopenia, and aging models. We further discuss current and emerging therapeutic strategies, including exercise, nutritional interventions, anti-osteoporotic agents, metabolic modulators, mitochondrial-targeted therapies, and gut-directed approaches. Longitudinal cohorts, multi-omics studies, and randomized controlled trials are urgently required to validate immunometabolic biomarkers and develop integrated interventions for osteosarcopenia.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate School, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
- School of Psychiatry, Wenzhou Medical University, Wenzhou 325035, China.
- Stroke Biological Recovery Laboratory, Spaulding Rehabilitation Hospital, The Teaching Affiliate of Harvard Medical School, Boston, MA 02129, USA.
- The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin 150001, China.
Förderung
- Heilongjiang Provincial Key Research and Development Pro-gram (Innovation Base)
- Heilongjiang Provincial Key Research and Development Program
Zitieren
APA
Zhang, Y., Li, Y., Luo, X., Wang, Q., Zhu, L., & Wang, Y. (2026). Immunometabolic Remodeling in Osteosarcopenia: Inflammaging, Mitochondrial Dysfunction, Gut-Derived Metabolites and Therapeutic Opportunities. Metabolites, 16(8), 556. https://doi.org/10.3390/metabo16080556
Vancouver
Zhang Y, Li Y, Luo X, Wang Q, Zhu L, Wang Y. Immunometabolic Remodeling in Osteosarcopenia: Inflammaging, Mitochondrial Dysfunction, Gut-Derived Metabolites and Therapeutic Opportunities. Metabolites. 2026;16(8):556. doi:10.3390/metabo16080556
BibTeX
@article{Zhang2026,
author = {Zhang, Yichi and Li, Yuntao and Luo, Xun and Wang, Qingmei and Zhu, Luwen and Wang, Yan},
title = {Immunometabolic Remodeling in Osteosarcopenia: Inflammaging, Mitochondrial Dysfunction, Gut-Derived Metabolites and Therapeutic Opportunities},
journal = {Metabolites},
year = {2026},
volume = {16},
number = {8},
pages = {556},
doi = {10.3390/metabo16080556}
}
EUVIMED